Woodline Partners’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Woodline Partners’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,352,048	Closed	-$27.3M	–	853
2021 Q3	$27.3M	Buy	1,352,048 +351,723	+35%	+$9.71M	0.45%	60
2021 Q2	$37.3M	Sell	1,000,325 -776,675	-44%	-$23.8M	0.7%	35
2021 Q1	$45.4M	Buy	1,777,000 +418,204	+31%	+$10.7M	1.01%	21
2020 Q4	$29.9M	Buy	1,358,796 +885,189	+187%	+$19.5M	0.79%	36
2020 Q3	$8.52M	Buy	473,607 +39,996	+9%	+$828K	0.28%	95
2020 Q2	$11M	Sell	433,611 -198,489	-31%	-$4.28M	0.44%	69
2020 Q1	$11.6M	Buy	632,100 +260,232	+70%	+$5.06M	0.83%	37
2019 Q4	$8.19M	Buy	+371,868	New	+$7.48M	0.33%	74

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.76B AUM 40.74% 1-Year Est. Return

Woodline Partners's DRNA Position: Q4 2021 in Review

Woodline Partners sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 1,352,048 shares — an estimated $27.3M sold.

Woodline Partners first reported a position in DRNA in Q4 2019 and held it in 8 quarters. The position peaked at $45.4M in Q1 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Woodline Partners reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Woodline Partners sold 1,352,048 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $27.3M.
Woodline Partners first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2019 and held it in 8 quarters.
Woodline Partners's Dicerna Pharmaceuticals, Inc. position peaked at $45.4M in Q1 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Woodline Partners's 13F filing for Q4 2021, filed 14 Feb 2022.